6 research outputs found
Intravitreal anti-VEGF therapy as an adjunct to laser photocoagulation for severe aggressive posterior retinopathy of prematurity
AbstractPurposeThe aim of the study was to evaluate the role of anti-VEGF therapy as an adjunct to laser ablation therapy in severe aggressive posterior retinopaty of prematurity (AP-ROP).MethodsMedical records of premature infants with a primary diagnosis of AP-ROP treated with 0.625mg/0.025ml intravitreal bevacizumab (IVB) in addition to standard laser photocoagulation as a salvage therapy or primarily combined with laser in a university clinic were reviewed, retrospectively. The anatomical results and complications were evaluated after treatment.Results15 eyes of 9 patients with a mean gestational age of 28.3 weeks (range, 26–31w) and mean birth weight of 1090g (range, 860–1330g) were included in the study. They all had Zone 1 or posterior Zone 2 plus disease staging between severe 3 and 4a. Twelve eyes were treatment naive at the beginning. The mean follow-up was 19.5±11.8 months (range, 11–40 months). The disease regressed totally in 6 eyes (40%), stayed stable as stage 4a in 1 eye (6.7%), progressed to and stabilized at stage 4a in 3 eyes (20%) and progressed to stage 5 in 3 eyes (20%) within 7–10 days. Two eyes (13.3%) developed hypotony and cataract.ConclusionThe association of IVB and laser ablation might decrease the progression rate in severe AP-ROP. Prompt regression of iris neovascularization encourages its use in cases with pupillary rigidity to allow for laser treatment. When used as a salvage therapy it may not change the overall result dramatically
Vitreus Hemorajisi Tedavisinde Pars Plana Vitrektomi ve Peroperatif İntravitreal Bevasizumab Enjeksiyonu.
Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy
Background/ aim: To evaluate refractive and strabismic results and the
efficacy of intravitreal bevacizumab in retinopathy of prematurity (ROP)
ineligible for laser therapy.
Materials and methods: Thirty-nine eyes of 20 consecutive infants with
high-risk prethreshold ROP (11 infants with Zone I and 9 infants with
Zone II disease) who were ineligible for laser therapy due to systemic
and/ or ocular conditions were treated with intravitreal bevacizumab.
Recurrent retinopathy was treated with laser ablation. The final
follow-up examination was performed at 29.8 +/- 6.0 months of corrected
age.
Results: All eyes responded to the initial treatment with intravitreal
bevacizumab. ROP recurred in 8 eyes (36\%) with initial Zone I disease
and in only 2 eyes (11\%) with initial Zone II disease, which were
successfully treated with laser ablation. No eye developed myopia higher
than 5.0 diopters. At 2.5 years, the Zone I eyes that had received laser
treatment appeared to be more myopic than the Zone I eyes treated only
with intravitreal bevacizumab (P = 0.038). A tendency for a higher
incidence of strabismus after additional laser therapy was also noted,
but was not significant (P = 0.22).
Conclusion: Avoidance or even deferral of laser ablation with
intravitreal bevacizumab may lead to less myopization in ROP compared
with conventional laser treatment